Advertisement
Australia markets closed
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • AUD/USD

    0.6538
    +0.0014 (+0.22%)
     
  • OIL

    83.82
    +0.25 (+0.30%)
     
  • GOLD

    2,361.50
    +19.00 (+0.81%)
     
  • Bitcoin AUD

    98,640.48
    +874.52 (+0.89%)
     
  • CMC Crypto 200

    1,391.13
    -5.41 (-0.39%)
     
  • AUD/EUR

    0.6090
    +0.0017 (+0.27%)
     
  • AUD/NZD

    1.0979
    +0.0022 (+0.20%)
     
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,110.81
    +31.95 (+0.40%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    18,038.25
    +120.97 (+0.68%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Gilead's Remdesivir First Drug to Win FDA Approval for Coronavirus

Gilead's Remdesivir First Drug to Win FDA Approval for Coronavirus

On Thursday, the U.S. Food and Drug Administration (FDA) granted approval to Gilead Sciences' (NASDAQ: GILD) remdesivir -- sold under the brand name Veklury -- to treat the illness in patients 12 years of age and older in cases requiring hospitalization. Gilead is currently developing an inhaled version. The FDA's approval was based on data from three clinical studies of the drug.